Expert Interview
Discussing the Potential of Summit's (SMMT) Ezutromid in Duchenne Muscular Dystrophy After Initiation of Phase 2 Enrollment
Ticker(s): SMMT, SRPTA muscular dystrophy expert familiar with treating DMD patients and the SMMT trials.
Can you describe your experience treating patients with DMD, and your familiarity with Ezutromid?
Added By: pjloriaWhat treatments are currently used for your patients, and how would you describe the safety and efficacy of these treatments? How do these treatments compare to Ezutromid? How does Ezutromid compare to Sarepta's Eteplirsen?
Added By: pjloriaEzutromid is a utrophin modulator, can you talk about this compound and its potential in DMD?
Added By: pjloriaWhat are your thoughts on the available data that has been presented on Ezutromid?
Added By: pjloriaThe Phase 2 study recently initiated enrollment. Can you give us your thoughts on the design and your expectations for the study?
Added By: pjloriaBased on your current knowledge, what is the potential for Ezutromid in the DMD? What are the chances the drug is approved?
Added By: pjloriaAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
